Acadia Pharmaceuticals says Appeals Court confirms validity of NUPLAZID patent

The company states: “Acadia Pharmaceuticals (ACAD) announced that the U.S. Court of Appeals for the Federal Circuit affirmed a decision issued by the U.S. District Court for the District of Delaware in December 2023 confirming validity of the NUPLAZID ‘740 composition of matter patent. The affirmance came in Acadia’s litigation against MSN Laboratories Pvt. Ltd. and MSN Pharmaceuticals, Inc. This follows the U.S. District Court for the District of Delaware ruling in favor of Acadia regarding its ‘721 formulation patent for NUPLAZID which ruled in favor of Acadia on both infringement and validity arguments in its formulation patent litigation against Aurobindo Pharma Limited and other ANDA filers.”